cannabidiol

EHP-101, an experimental treatment being clinically tested for multiple sclerosis (MS), activates a cellular signaling pathway that promotes blood vessel development and reduces inflammation following brain injury, a new study shows. The findings continue to support the use of EHP-101 in MS, a condition marked by excess inflammation and…

Treatment with cannabis-based medications may ease muscle spasms, decrease pain, and aid in sleep for people with multiple sclerosis (MS), but more research is needed to evaluate the potential benefits of cannabis use. That is the finding of a team of U.S. researchers who published a review paper, “…

Epstein-Barr Virus May be Leading Cause of MS, Raising Risk by 32 Times Several studies over the past few years have suggested a link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), but this one is huge, both in the number of participants and in the length…

Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or…

Open Book Extracts (OBX) and Case Western Reserve University School of Medicine have partnered to investigate how cannabinoids like CBD affect brain cells, particularly in regard to neuroinflammation, according to an OBX press release. CBD (cannabidiol) and other cannabinoids, such as THC (tetrahydrocannabinol), have attracted interest for…

People in Texas with multiple sclerosis (MS) and other medical conditions now have access to cannabis-infused lozenges, Surterra Texas announced. Under a Texas Compassionate Use Program, cannabis-containing therapies may be prescribed to help treat various neurological and other disorders, including terminal cancer, spasticity,…

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other…

EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health Pharmaceuticals (EHP) to treat multiple sclerosis (MS), is not a controlled substance in Canada, the company announced. The active ingredient in EHP-101 is a derivative of cannabidiol, abbreviated CBD. This is one of the most well-known active compounds in…

A joint analysis of 83 studies, involving 3,000 people, concluded that there is “scarce evidence” to say that the use of medicinal cannabinoids — chemical compounds in the cannabis plant — is able to improve mental health conditions. However, the use of pharmaceutical tetrahydrocannabinol (THC) may lead to…

The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for their…

The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed, Emerald Health Pharmaceuticals (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development of EHP-101 in future Phase 2 clinical trials. The…

“Diet is profound. Lifestyle is profound. All patients should be taught how profound these things are.”  — Terry Wahls, MS thriver and founder of the Wahls Protocol  Western medicine has long approached multiple sclerosis (MS) and autoimmune disorders through traditional methods. While there have been…

Valeritas Holdings‘ proprietary h-Patch device can be used to administer cannabidiol by an under-the-skin (subcutaneous) infusion, prolonging the time the medication remains in circulation in the body and maximizing its therapeutic effects, a preclinical study has found. Cannabidiol (CBD) is a cannabis-derived, purified liquid formulation that has…

EHP-101, a cannabidiol-based experimental therapy for multiple sclerosis, was able to recover myelin in damaged nerve fibers and lessen neuroinflammation in a mouse model of MS, data show. Emerald Health Therapeutics, the manufacturer of EHP-101, also announced plans to open Phase 2 clinical trials in patients by…

The U.S. Drug Enforcement Administration (DEA) has determined that the cannabidiol-based active ingredient of EHP-101, an investigational oral treatment for multiple sclerosis (MS) under development by Emerald Health Pharmaceuticals (EHP), should not be classified…

Emerald Health Pharmaceuticals announced that it has begun enrolling healthy volunteers for a Phase 1 clinical trial evaluating the safety and tolerability of EHP-101, a potential cannabidiol treatment for multiple sclerosis (MS) and scleroderma. The randomized, double-blind, and placebo-controlled study (ACTRN12618001390279p) will  investigate the safety and pharmacokinetics (how…

Cannabidiol Increases Inflammatory Suppressor Cells, New MS Mouse Study Shows There’s quite a bit of anecdotal evidence that the use of marijuana can help reduce the symptoms of multiple sclerosis (MS). Here’s a report about a study that suggests a reason that could be happening. Non-psychoactive cannabidiol (CBD),…

Non-psychoactive cannabidiol (CBD), one of the active compounds in medical cannabis, significantly reduced clinical signs of multiple sclerosis (MS)-like disease in an experimental autoimmune encephalomyelitis mouse model. Researchers found that CBD promoted the increase of inflammatory-suppressor cells called myeloid-derived suppressor cells. The findings were reported in the study “Cannabidiol Attenuates Experimental Autoimmune…

Carmen Navarrete, PhD, has been granted a Scientific Innovation Award for her post-doctoral presentation suggesting that the multiple sclerosis (MS) treatment candidate EHP-101 is anti-inflammatory and may boost remyelination, Emerald Health Pharmaceuticals announced. Navarrete, a senior scientist at Vivacell Biotechnology Espana, a company owned by Emerald Health Research, received the award at the…

Researchers confirmed that Sativex spray is beneficial in alleviating pain in patients with multiple sclerosis (MS), and also improved their pain sensitivity to cold temperatures. The study reporting the findings, “Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX) in Patients with Multiple Sclerosis: A Study with Quantitative…

Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But there is still much to be done to enhance their use and accessibility to patients who may benefit from these therapies, according to…

Emerald Health‘s investigational cannabidiol-derived EHP-101 reduces neuroinflammation, the risk of loss of myelin, and nerve cell damage in two mouse models of multiple sclerosis (MS), a new study shows. These results support the potential therapeutic benefits of EHP-101 for MS, and Emerald Health Pharmaceuticals expects to launch a human…